BioSpace News Archive

The global muscle wasting disorder market is fueled primarily by the rising adherence to a sedentary lifestyle in developed regions.

Microalbuminuria is a condition that affects the kidney and restricts in retaining serum albumin, which is considered as a vital factor for the kidney to maintain its overall health of the body.

Albany NY, United States: A laboratory equipment used to mix, agitate, or blend substances in a tube or flask by shaking them is known as laboratory shaker.

Curium announced it has successfully enrolled and dosed patients in the ECLIPSE Trial.

Innate Pharma SA, announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2022.

Ipsen announced that the European Commission has approved the use of Cabometyx® as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.

reMYND NV, a clinical stage company tackling neurodegeneration, announces that its lead Alzheimer program ReS19-T has successfully completed its Phase 1 study.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2022, and provides a corporate update.

Isofol Medical AB, will publish the company’s results for the first quarter of 2022 on Thursday, May 12, 2022.

BioInvent International AB announces its novel anti-FcyRIIB antibody BI-1206 is progressing into the expansion phase of a Phase 1/2a trial for non-Hodgkin’s lymphoma, following a positive End-of-Phase 1 meeting with the US FDA.